Table 1.
Summary of antisense drugs approved or in clinical trials
| Drug name | Drug target | Cardiovascular effect | Current status |
|---|---|---|---|
| Kynamro | Apolipoprotein B | Lowers plasma apoB, TPC, LDL-C, non-HDL-C, and Lp(a) | FDA approval for its use as an adjunct to lipid-lowering medications for homozygous FH patients |
| SPC4955 | Apolipoprotein B | Lowers plasma apoB, TPC, LDL-C, non-HDL-C, and Lp(a) | Phase I (completed) |
| ApoC-IIIRx | Apolipoprotein C-III | Lowers plasma apoC-III and TG | Phase I (completed), Phase II initiated |
| FXIRx | Factor XI | Prevents thrombosis | Phase I (completed) |
| BMS-844421 | PCSK9 | Lowers plasma apoB, TPC, LDL-C, and non-HDL-C | Phase I (terminated) |
| SPC5001 | PCSK9 | Lowers plasma apoB, TPC, LDL-C, and non-HDL-C | Phase I (terminated) |
| ALN-PCS02 | PCSK9 | Lowers plasma apoB, TPC, LDL-C, and non-HDL-C | Phase I (completed) |
| ApoARx | Apolipoprotein(a) | Lowers Lp(a) | Phase I initiated |
TPC total plasma cholesterol